CA
NZ
UK
AU
IND
US
Aethlon Medical, Inc. (NASDAQ: AEMD) agreed to an all-stock transaction with North Immunology, complemented by an intended $180 million private financing, with the combined entity set to operate under the North Immunology name and ticker symbol NRTX.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) entered into a Memorandum of Understanding alongside King Abdullah International Medical Research Center and the Foundation for Neurologic Diseases to evaluate intranasal foralumab in combination with anti-CD20 therapy within a clinical trial targeting non-responding relapsing-remitting multiple sclerosis patients.
Barclays downgraded Cellectis S.A. (NASDAQ: CLLS) from Overweight to Underweight on September 16, 2026, significantly reducing its price target from $9.00 to $1.30.
Novo Nordisk (NYSE:NVO) shares dropped sharply pre-market as its Capital Markets Day in London failed to convince investors the company can defend its position in the weight-loss drug market it helped create. CEO Mike Doustdar laid out plans to launch more than five drugs …
Amneal Pharmaceuticals (NASDAQ:AMRX) shares are trading lower in pre-market action despite a positive catalyst last week, as the stock retreats after a strong run tied to the FDA approval and immediate launch of its generic version of a branded injectable treatment for acromegaly and …
bioAffinity Technologies (NASDAQ:BIAF) shares are trading lower in pre-market action even after the company announced a new intellectual property win in Asia. The Hong Kong Intellectual Property Department granted a patent covering the company's proprietary platform technology, which uses flow cytometry and fluorescent markers …
CapsoVision (NASDAQ:CV) shares moved higher in pre-market trading after the company agreed to a registered direct offering priced at a modest discount to market. The deal, approved by the company's board and reviewed by its audit committee, was funded entirely by existing shareholders rather …
Nanobiotix (NASDAQ:NBTX) shares pulled back sharply in Friday's session as investors booked profits and digested mixed new clinical data, following a rally that had taken shares up roughly 283% over the past year. Nanobiotix is a Paris-based, late clinical-stage biotechnology company pioneering physics-based nanotherapeutics, …
Xenon Pharmaceuticals (NASDAQ:XENE) shares extended their decline through Friday's session, falling as much as 30.39% by the afternoon after opening the day down roughly 24% following the company's disclosure of a voluntary pause in new patient enrollment for its azetukalner studies in major depressive …
XORTX Therapeutics (NASDAQ:XRTX) shares jumped in Friday's session after the company outlined its anticipated Investigational New Drug application submission to the FDA for its XRx-026 gout program, planned for the fourth quarter of 2026. XORTX is a late-stage clinical pharmaceutical company headquartered in Calgary, …
Please wait processing your request...